Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 3258-02-4 Chemical Structure| 3258-02-4

Structure of EIDD-1931
CAS No.: 3258-02-4

Chemical Structure| 3258-02-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

EIDD-1931 has a broad-spectrum antiviral activity against multiple coronaviruses, including SARS-CoV2, MERS-CoV, SARS-CoV. and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Zabek, Magdalene ;

Abstract: and nirmatrelvir are effective COVID-19 therapeutics, however there is limited data on their safety during pregnancy. The objective is to quantify the placental transfer of nirmatrelvir and (NHC), the metabolite of found in plasma. A systematic review on the pharmacokinetics of nirmatrelvir found no data in pregnant subjects, though several studies reported parameters in non-pregnant individuals such as CL, VD, and fu. Using the ex vivo human placental perfusion model, nirmatrelvir showed a fetal-maternal concentration ratio (F:M) of 0.34 at therapeutic doses (2.21 µg/mL) and 0.46 (22.1 µg/mL) at supratherapeutic doses. Adjusted F:M for non-placental physiological factors ranged from 0.26-0.35 (2.21 µg/mL) and 0.38-0.51 (22.1 µg/mL). For , the F:M was (2.97µg/mL) and (29.7 µg/mL). Results suggest that therapeutic and supratherapeutic doses of nirmatrelvir and can passively cross the placental barrier. This data can be considered to create better safety recommendations regarding their use in pregnancy.

Keywords: COVID-19 ; placental perfusion ; pregnancy ; nirmatrelvir ; ; pharmacokinetics ; placental transfer ; drug safety ; nucleoside analogue ; main protease inhibitor

Purchased from AmBeed: ;

Alternative Products

Product Details of EIDD-1931

CAS No. :3258-02-4
Formula : C9H13N3O6
M.W : 259.22
SMILES Code : O=C1N/C(C=CN1[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)=N/O
MDL No. :MFCD01675695
InChI Key :XCUAIINAJCDIPM-XVFCMESISA-N
Pubchem ID :197020

Safety of EIDD-1931

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H315-H319-H228
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313
Class:4.1
UN#:1325
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HoxA9-Meis1-transformed myeloid cells 1 μM 8 days To assess the impact of EIDD-1931 on cell growth. EIDD-1931 treatment slowed the growth rate of cells. PMC10711452
E μ-Myc lymphoma cells 0–10 μM 48 hours To assess the impact of EIDD-1931 on cell survival and proliferation. EIDD-1931 treatment reduced proliferation and viability in both cell types, but only at relatively high concentrations ( E μ-Myc , IC50 = 1.0 μM, 95% CI 0.61–1.6 μM; HoxA9-Meis1 IC50 = 3.8 μM, 95% CI 1.2–12 μM). PMC10711452

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.86mL

0.77mL

0.39mL

19.29mL

3.86mL

1.93mL

38.58mL

7.72mL

3.86mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories